Cargando…
Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice
Endogenously administered activated protein C ameliorates diabetic nephropathy (DN) in a protease-activated receptor-1 (PAR-1)-dependent manner, suggesting that PAR-1 activation limits the progression of DN. Activation of PAR-1 in fibroblast-like cells, however, induces proliferation and extracellul...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020504/ https://www.ncbi.nlm.nih.gov/pubmed/27618774 http://dx.doi.org/10.1038/srep33030 |
_version_ | 1782453215813435392 |
---|---|
author | Waasdorp, Maaike Duitman, JanWillem Florquin, Sandrine Spek, C. Arnold |
author_facet | Waasdorp, Maaike Duitman, JanWillem Florquin, Sandrine Spek, C. Arnold |
author_sort | Waasdorp, Maaike |
collection | PubMed |
description | Endogenously administered activated protein C ameliorates diabetic nephropathy (DN) in a protease-activated receptor-1 (PAR-1)-dependent manner, suggesting that PAR-1 activation limits the progression of DN. Activation of PAR-1 in fibroblast-like cells, however, induces proliferation and extracellular matrix production, thereby driving fibrotic disease. Considering the key role of mesangial proliferation and extracellular matrix production during DN, PAR-1 may in fact potentiate diabetes-induced kidney injury. To determine the net effect of PAR-1 in DN, streptozotocin-induced DN was studied in wild type and PAR-1 deficient mice. Subsequent mechanistic insight was obtained by assessing profibrotic responses of mesangial and tubular epithelial cells in vitro, following PAR-1 stimulation and inhibition. Despite having similar glucose levels, PAR-1 deficient mice developed less kidney damage after induction of diabetes, as evidenced by diminished proteinuria, plasma cystatin C levels, expansion of the mesangial area, and tubular atrophy. In vitro, PAR-1 signaling in mesangial cells led to increased proliferation and expression of matrix proteins fibronectin and collagen IV. Conversely, a reduction in both proliferation and fibronectin deposition was observed in diabetic PAR-1 deficient mice. Overall, we show that PAR-1 plays an important role in the development of DN and PAR-1 might therefore be an attractive therapeutic target to pursue in DN. |
format | Online Article Text |
id | pubmed-5020504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50205042016-09-20 Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice Waasdorp, Maaike Duitman, JanWillem Florquin, Sandrine Spek, C. Arnold Sci Rep Article Endogenously administered activated protein C ameliorates diabetic nephropathy (DN) in a protease-activated receptor-1 (PAR-1)-dependent manner, suggesting that PAR-1 activation limits the progression of DN. Activation of PAR-1 in fibroblast-like cells, however, induces proliferation and extracellular matrix production, thereby driving fibrotic disease. Considering the key role of mesangial proliferation and extracellular matrix production during DN, PAR-1 may in fact potentiate diabetes-induced kidney injury. To determine the net effect of PAR-1 in DN, streptozotocin-induced DN was studied in wild type and PAR-1 deficient mice. Subsequent mechanistic insight was obtained by assessing profibrotic responses of mesangial and tubular epithelial cells in vitro, following PAR-1 stimulation and inhibition. Despite having similar glucose levels, PAR-1 deficient mice developed less kidney damage after induction of diabetes, as evidenced by diminished proteinuria, plasma cystatin C levels, expansion of the mesangial area, and tubular atrophy. In vitro, PAR-1 signaling in mesangial cells led to increased proliferation and expression of matrix proteins fibronectin and collagen IV. Conversely, a reduction in both proliferation and fibronectin deposition was observed in diabetic PAR-1 deficient mice. Overall, we show that PAR-1 plays an important role in the development of DN and PAR-1 might therefore be an attractive therapeutic target to pursue in DN. Nature Publishing Group 2016-09-13 /pmc/articles/PMC5020504/ /pubmed/27618774 http://dx.doi.org/10.1038/srep33030 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Waasdorp, Maaike Duitman, JanWillem Florquin, Sandrine Spek, C. Arnold Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice |
title | Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice |
title_full | Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice |
title_fullStr | Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice |
title_full_unstemmed | Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice |
title_short | Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice |
title_sort | protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020504/ https://www.ncbi.nlm.nih.gov/pubmed/27618774 http://dx.doi.org/10.1038/srep33030 |
work_keys_str_mv | AT waasdorpmaaike proteaseactivatedreceptor1deficiencyprotectsagainststreptozotocininduceddiabeticnephropathyinmice AT duitmanjanwillem proteaseactivatedreceptor1deficiencyprotectsagainststreptozotocininduceddiabeticnephropathyinmice AT florquinsandrine proteaseactivatedreceptor1deficiencyprotectsagainststreptozotocininduceddiabeticnephropathyinmice AT spekcarnold proteaseactivatedreceptor1deficiencyprotectsagainststreptozotocininduceddiabeticnephropathyinmice |